Literature DB >> 29414482

Reducing opioid overdose in Kazakhstan: A randomized controlled trial of a couple-based integrated HIV/HCV and overdose prevention intervention "Renaissance".

Louisa Gilbert1, Timothy Hunt2, Sholpan Primbetova2, Assel Terlikbayeva2, Mingway Chang2, Elwin Wu2, Tara McCrimmon2, Nabila El-Bassel2.   

Abstract

OBJECTIVES: To evaluate the efficacy of a couple-based integrated HIV/HCV and overdose prevention intervention on non-fatal and fatal overdose and overdose prevention behaviors among people who use heroin or other opioids in Almaty, Kazakhstan.
METHODS: We selected 479 participants who reported lifetime heroin or opioid use from a sample of 600 participants (300 couples) enrolled in a randomized controlled trial (RCT) conducted between May 2009 and February 2013. Participants were randomized to either (1) a 5-session couple-based HIV/HCV and overdose prevention intervention condition or (2) a 5-session Wellness Promotion and overdose prevention comparison condition. We used multilevel mixed-effects model with modified Poisson regression to estimate effects of the intervention as risk ratios (RR) and the corresponding 95% CIs.
RESULTS: About one-fifth (21.9%) of the sample reported that they had experienced an opioid overdose in the past 6 months at baseline. At the 12-month follow-up, both the intervention and comparison conditions reported significant reductions in non-fatal overdose and injection heroin/opioid use and significant increases in drug treatment attendance and naloxone use to prevent death from overdose. However, we found no differences between the study arms on any of these outcomes. There were three intervention condition participants (1.3%), compared to seven comparison condition participants (2.9%) who died from opioid overdose during the 12-month follow up period although this difference was not significant. DISCUSSION: There were no significant conditions on any outcomes: both conditions showed promising effects of reducing non-fatal overdose and overdose risks. Integrating overdose prevention into a couple-based HIV/HCV intervention may be an efficient strategy to target the syndemic of opioid overdose, HIV and HCV in Kazakhstan.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HCV; HIV; Injection drug use; Opioid overdose

Mesh:

Substances:

Year:  2018        PMID: 29414482      PMCID: PMC5899623          DOI: 10.1016/j.drugpo.2018.01.004

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  27 in total

1.  Current Progress in Opioid Treatment.

Authors:  George E Woody
Journal:  Am J Psychiatry       Date:  2017-05-01       Impact factor: 18.112

2.  The Role of Science in Addressing the Opioid Crisis.

Authors:  Nora D Volkow; Francis S Collins
Journal:  N Engl J Med       Date:  2017-05-31       Impact factor: 91.245

Review 3.  Novel interventions to prevent HIV and HCV among persons who inject drugs.

Authors:  Phillip O Coffin; Christopher Rowe; Glenn-Milo Santos
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities.

Authors:  Leo Beletsky; Robin Ruthazer; Grace E Macalino; Josiah D Rich; Litjen Tan; Scott Burris
Journal:  J Urban Health       Date:  2007-01       Impact factor: 3.671

5.  Self-efficacy: toward a unifying theory of behavioral change.

Authors:  A Bandura
Journal:  Psychol Rev       Date:  1977-03       Impact factor: 8.934

Review 6.  Couple-based HIV prevention in the United States: advantages, gaps, and future directions.

Authors:  Nabila El-Bassel; Louisa Gilbert; Susan Witte; Elwin Wu; Tim Hunt; Robert H Remien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

7.  Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial.

Authors:  Nabila El-Bassel; Louisa Gilbert; Assel Terlikbayeva; Chris Beyrer; Elwin Wu; Mingway Chang; Tim Hunt; Leyla Ismayilova; Stacey A Shaw; Sholpan Primbetova; Yelena Rozental; Baurzhan Zhussupov; Marat Tukeyev
Journal:  J Acquir Immune Defic Syndr       Date:  2014-10-01       Impact factor: 3.731

Review 8.  A systematic review of community opioid overdose prevention and naloxone distribution programs.

Authors:  Angela K Clark; Christine M Wilder; Erin L Winstanley
Journal:  J Addict Med       Date:  2014 May-Jun       Impact factor: 3.702

9.  Social mixing and correlates of injection frequency among opioid use partnerships.

Authors:  Christopher Rowe; Glenn-Milo Santos; Henry F Raymond; Phillip O Coffin
Journal:  Int J Drug Policy       Date:  2017-01-20

10.  Randomized controlled trial of a computerized opioid overdose education intervention.

Authors:  Kelly E Dunn; Claudia Yepez-Laubach; Paul A Nuzzo; Michael Fingerhood; Anne Kelly; Suzan Berman; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2017-04-01       Impact factor: 4.492

View more
  3 in total

1.  A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.

Authors:  Hawraa Sameer Sajwani; Anna V Williams
Journal:  Harm Reduct J       Date:  2022-10-20

2.  Integrating HIV services and other health services: A systematic review and meta-analysis.

Authors:  Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen
Journal:  PLoS Med       Date:  2021-11-09       Impact factor: 11.069

3.  An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine.

Authors:  Paul Dietze; Gilberto Gerra; Vladimir Poznyak; Giovanna Campello; Wataru Kashino; Dzhonbek Dzhonbekov; Tetiana Kiriazova; Danil Nikitin; Assel Terlikbayeva; Dzmitry Krupchanka; Anja Busse
Journal:  Bull World Health Organ       Date:  2022-02-03       Impact factor: 9.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.